MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

MetaVia Inc. announced positive preclinical data for its drug candidate DA-1241 in combination with Efruxifermin (EFX) for treating MASH, showing additive hepatoprotective effects in a mouse model. The combination therapy resulted in a statistically significant improvement in NAFLD activity score in 94% of mice and greater reductions in liver inflammation and fibrosis compared to either monotherapy, suggesting a potential for enhanced therapeutic benefit. These results build on encouraging Phase 2a trial results of DA-1241, which demonstrated hepatoprotective and glucose-regulating effects.

Analysis

MetaVia Inc. (MTVA) has presented strongly positive pre-clinical data for its MASH drug candidate, DA-1241, in a combination therapy with Efruxifermin. The study in a mouse model demonstrated a significant additive effect, with 94% of mice receiving the combination achieving a ≥2-point improvement in the NAFLD activity score, a superior outcome compared to either monotherapy. This enhanced therapeutic potential appears independent of weight loss, as the combination did not induce additional weight reduction beyond the 17% seen with Efruxifermin alone, isolating the direct hepatoprotective benefits. The combination also produced greater reductions in key inflammatory and fibrotic markers, such as TNFα (-58%), CCL2 (-77%), and type 1 collagen α1 (-72%) gene expression. These findings build upon encouraging Phase 2a results for DA-1241, strengthening the scientific rationale for its development as a combination agent in the competitive MASH therapeutic landscape. While this news reinforces the potential of MetaVia's pipeline, which also includes the promising obesity candidate DA-1726, an appended note from an external analysis firm suggests the company's stock may not be considered a top undervalued pick by quantitative models, providing a cautious counterpoint to the positive scientific update.

Key Decisions for Investors

• The positive pre-clinical combination data for DA-1241 significantly strengthens the asset's profile for treating MASH, and investors should view this as a key de-risking event for this part of MetaVia's pipeline.
• Despite the strong scientific results, investors must weigh the early-stage nature of this pre-clinical data against the long and high-risk path to commercialization, as reflected in the moderate market impact score.
• Given the contrast between the positive pipeline news and the external commentary on valuation, it is prudent to monitor for upcoming clinical trial data for both DA-1241 and the obesity drug DA-1726 as key future catalysts.